Clinical Trials on NSCLC, Stage I in China

Total 1021 results

Guangdong Provincial People's Hospital

Recruiting

Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection

NSCLC, Stage I | Disease Free Survival | Pulmonary Function Assessment

China
Xiaorong Dong

Unknown

The Role of Microbiota on the Development of Lung Cancer

Healthy Subjects | NSCLC Stage IV | NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China
Shanghai Chest Hospital
The Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...

Recruiting

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018)

NSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIIC

China
Peking Union Medical College

Recruiting

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, Recurrent

China
Shanghai Pharmaceuticals Holding Co., Ltd

Withdrawn

Phase I Study of SPH1188-11 in NSCLC (SPH1188-11)

NSCLC Stage IV | NSCLC Stage IIIB

China
Zhejiang Cancer Hospital

Recruiting

TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors

SCLC,Extensive Stage

China
Shandong Provincial Hospital

Unknown

Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer

Stage I NSCLC

China
Daping Hospital and the Research Institute of Surgery...

Completed

Combination of Metformin With Gefitinib to Treat NSCLC (CGMT)

NSCLC | Advanced Cancer | EGFR Gene Amplification | Stage IV NSCLC | Stage IIIB NSCLC

China
Beijing Tsinghua Chang Gung Hospital

Recruiting

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

NSCLC, Stage III

China
Xiaolong Yan, Dr.

Enrolling by invitation

Comparison of Segmentectomy and Lobectomy in Small (2 cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study

NSCLC, Stage I

China
Fudan University

Unknown

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC (PCA)

NSCLC Stage IV

China
Fujian Cancer Hospital

Unknown

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Chemotherapy Effect | NSCLC Stage IV

China
Shanghai Chest Hospital
Bristol-Myers Squibb

Completed

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

NSCLC Stage IV | Checkpoint Inhibitor

China
Shanghai Chest Hospital

Recruiting

Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations

NSCLC | NSCLC Stage IV | NSCLC, Recurrent

China
Fudan University

Not yet recruiting

Prospective Observation of Failure Patterns in NSCLC Treated With ICIs

NSCLC Stage IV | NSCLC, Recurrent

China
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd.

Recruiting

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer (EFLRWR)

NSCLC Stage IV | NSCLC Stage IIIB | ALK Positive

China
Shanghai Zhongshan Hospital
Shanghai Changzheng Hospital

Recruiting

Selenious Yeast in CLL Patients w/o Indication of Chemotherapy

Chronic Lymphocytic Leukemia Stage A(0) | Chronic Lymphocytic Leukemia Stage A(I) | Chronic Lymphocytic Leukemia Stage A(II) | Chronic Lymphocytic Leukaemia Stage B(I)

China
Beijing Friendship Hospital
Beijing Health Promotion Association

Recruiting

Comparison Between Prepectoral and Subpectoral Breast Reconstruction (RESPECT)

Stage I Breast Cancer | Stage II Breast Cancer

China
Kiang Wu Hospital

Completed

Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

NSCLC Stage IV

China
Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Active, not recruiting

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

NSCLC, Stage III

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
Fudan University

Recruiting

SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

NSCLC Stage IV

China
Zhejiang Cancer Hospital

Recruiting

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

NSCLC Stage IV

China
The First People's Hospital of Lianyungang
Hengrui Yuanzheng Bio-Technology Co., Ltd.

Unknown

Neo-MASCT Immunotherapy for Advanced NSCLC.

NSCLC Stage IV

China
Shandong Provincial Hospital

Unknown

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (MWA in NSCLC)

NSCLC Stage IV

China
Yuan Chen

Recruiting

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

NSCLC, Stage III

China
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NSCLC Stage IV

China
Eucure (Beijing) Biopharma Co., Ltd

Withdrawn

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)

HCC | NSCLC Stage IV | NSCLC Stage IIIB

China, Australia, Taiwan, Armenia, Austria
The Affiliated Hospital of Qingdao University

Unknown

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NSCLC Stage IV | PD-1 | ARID1A

China
Shanghai Zhongshan Hospital
Shanghai Minhang Central Hospital; Xuhui Central Hospital, Shanghai; Zhongshan... and other collaborators

Completed

Surgery for Masaoka-Koga I-II Thymoma

Thymoma | Masaoka Stage I | Masaoka Stage II

China
Tang-Du Hospital

Recruiting

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

NSCLC Stage IV | Oligometastasis

China
Fudan University

Completed

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

NSCLC Stage IV | EGFR Activating Mutation

China
Akeso

Completed

Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

SCLC, Extensive Stage

China
Baodong Qin

Unknown

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

NSCLC Stage IV | Anlotinib | EGFR T790M-negative | JS001

China
The First Affiliated Hospital of Henan University...

Unknown

Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer

Stage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma | Stage I Esophageal Adenocarcinoma | Stage II Esophageal Adenocarcinoma | Stage III Esophageal Adenocarcinoma | Stage I Esophageal Squamous Cell Carcinoma

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MF

China
Fujian Medical University Union Hospital

Recruiting

Postoperative Chronic Operation-related Symptoms After Minimally Invasive Lung Surgery

Quality of Life | Lung Cancer Stage I

China
Second Affiliated Hospital, School of Medicine,...
GeneCast Biotechnology Co., Ltd.

Recruiting

Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy

Stage I-III Breast Cancer

China
Fudan University

Recruiting

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Breast Cancer Stage I

China
The Fourth Affiliated Hospital of Anhui Medical...

Completed

Precise Gene Signature for Predicting Outcomes in PDAC

Stage I-II Pancreatic Ductal Adenocarcinoma (PDAC) | Precise Prognostic and Predictive Signature

China
Shanghai Henlius Biotech

Completed

Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects

NSCLC

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects

NSCLC

China
Beta Pharma, Inc.

Completed

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

NSCLC

China
Affiliated Hospital of Nantong University
Tongzhou District Hospital; Haimen People's Hospital; Dongtai People's Hospital; Qidong City People's Hospital and other collaborators

Recruiting

Laparoscopic Gastric Function Preserving Surgery Combined With Resection of the Anterior Lymphatic Drainage Area

Gastric Cancer Stage I

China
Jiangsu Province Nanjing Brain Hospital

Recruiting

The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

NSCLC

China

Clinical Trials on NSCLC, Stage I in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations